TAVANTA

Serial Number 90845441
732

Registration Progress

Application Filed
Jul 23, 2021
Under Examination
May 2, 2023
Approved for Publication
Mar 7, 2023
Published for Opposition
Mar 7, 2023
Registered

Trademark Image

TAVANTA

Basic Information

Serial Number
90845441
Filing Date
July 23, 2021
Published for Opposition
March 7, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
732
Status Date
Nov 4, 2024
Application
Pending
Classes
005 042

Rights Holder

Tavanta Therapeutics, Inc.

03
Address
Suite 650
201 King of Prussia Road
Radnor, PA 19087

Ownership History

Tavanta Therapeutics, Inc.

Original Applicant
03
Radnor, PA

Tavanta Therapeutics, Inc.

Owner at Publication
03
Radnor, PA

Legal Representation

Attorney
C. BRANDON BROWNING

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

37 events
Date Code Type Description Documents
Sep 30, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 2, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 2, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
May 2, 2025 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Nov 5, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 5, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Nov 4, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 4, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 3, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 2, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 2, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
May 2, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 4, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 2, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 2, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 2, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
May 2, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 7, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 7, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 15, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 30, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 30, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 30, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 30, 2023 ALIE A ASSIGNED TO LIE Loading...
Nov 29, 2022 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Oct 27, 2022 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Oct 27, 2022 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Oct 27, 2022 CNSL R SUSPENSION LETTER WRITTEN Loading...
Oct 19, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 18, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 18, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 18, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 18, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 18, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 18, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 23, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 27, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Housemark for a full line of prescription pharmaceuticals for the treatment of cancer, anal fissures, cystic fibrosis; pharmaceuticals for treatment of cancer, and cystic fibrosis; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, cystic fibrosis, and anal fissures
Class 042
Providing information about medical and scientific research; Providing information about medical and scientific research via a website

Classification

International Classes
005 042